Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane.
about
A YKL-40-neutralizing antibody blocks tumor angiogenesis and progression: a potential therapeutic agent in cancersUnderstanding and treating triple-negative breast cancerThe fate of chemoresistance in triple negative breast cancer (TNBC)The Emerging Regulation of VEGFR-2 in Triple-Negative Breast CancerAntiangiogenesis therapy for breast cancer: an update and perspectives from clinical trialsCirculating biomarkers of response to sunitinib in gastroenteropancreatic neuroendocrine tumors: current data and clinical outlookTargeting triple-negative breast cancer: optimising therapeutic outcomesMicroRNAs and triple negative breast cancerNewer therapies for the treatment of metastatic breast cancer: a clinical updateHypertension in patients with cancerAngiogenesis and Antiangiogenesis in Triple-Negative Breast cancerSunitinib in solid tumorsMolecular phenotypes in triple negative breast cancer from African American patients suggest targets for therapyPrediction of cancer drugs by chemical-chemical interactionsEvolving Therapies and FAK Inhibitors for the Treatment of CancerAccelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesisIdentification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapiesPhase II study of sunitinib as second-line treatment for advanced gastric cancer.Phase I trial with biomarker studies of vatalanib (PTK787) in patients with newly diagnosed glioblastoma treated with enzyme inducing anti-epileptic drugs and standard radiation and temozolomide.Phase II study of sunitinib malate in patients with recurrent high-grade glioma.Sunitinib in combination with paclitaxel plus carboplatin in patients with advanced solid tumors: phase I study resultsPhase I and pharmacokinetic study of sunitinib in pediatric patients with refractory solid tumors: a children's oncology group study.Phase II open-label study of sunitinib in patients with advanced breast cancer.Sunitinib in combination with gemcitabine for advanced solid tumours: a phase I dose-finding study.Phase I study of sunitinib plus S-1 and cisplatin in Japanese patients with advanced or metastatic gastric cancer.Sunitinib combined with pemetrexed and carboplatin in patients with advanced solid malignancies--results of a phase I dose-escalation study.Multicenter phase II study of apatinib, a novel VEGFR inhibitor in heavily pretreated patients with metastatic triple-negative breast cancer.Sunitinib as salvage treatment including potent anti-tumor activity in carcinomatous ulcers for patients with multidrug-resistant metastatic breast cancerCurrent data of targeted therapies for the treatment of triple-negative advanced breast cancer: empiricism or evidence-based?Oral anticancer drugs: how limited dosing options and dose reductions may affect outcomes in comparative trials and efficacy in patients.Complete longitudinal analyses of the randomized, placebo-controlled, phase III trial of sunitinib in patients with gastrointestinal stromal tumor following imatinib failure.Noninvasive assessment of tumor VEGF receptors in response to treatment with pazopanib: a molecular imaging studyMolecular mechanisms of resistance to tumour anti-angiogenic strategiesSunitinib significantly suppresses the proliferation, migration, apoptosis resistance, tumor angiogenesis and growth of triple-negative breast cancers but increases breast cancer stem cells.Impact of metronomic UFT/cyclophosphamide chemotherapy and antiangiogenic drug assessed in a new preclinical model of locally advanced orthotopic hepatocellular carcinoma.Vascular endothelial growth factor receptor-1 mRNA overexpression in peripheral blood as a useful prognostic marker in breast cancerVEGFR2 heterogeneity and response to anti-angiogenic low dose metronomic cyclophosphamide treatment.Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer.Combination antiangiogenic therapy in advanced breast cancer: a phase 1 trial of vandetanib, a VEGFR inhibitor, and metronomic chemotherapy, with correlative platelet proteomicsEstrogen Receptor-β and the Insulin-Like Growth Factor Axis as Potential Therapeutic Targets for Triple-Negative Breast Cancer.
P2860
Q24595527-BBB0A1FA-A8AC-4F23-A784-BC5EDF2C1C6AQ24620957-FE25614E-9746-4274-8403-55ABF10E2216Q26775232-93D179D5-31B9-438A-B634-936BE7CAC0C9Q26779248-9601B770-ECAD-419A-B5E8-FB27D628F215Q26822432-249580B5-761A-43B5-9E3D-7D8B471C0944Q26823035-2F836D82-1D73-435B-B4BC-D9FE58668C56Q26850892-1842E12A-0451-4535-A8A8-2F6623618D41Q26862716-918F5C2B-CDF4-41FB-981B-B12143BF8A20Q26865260-051D905B-B706-4911-A539-1FF3408EC926Q27003980-71EC398A-36EC-4EDD-9619-C070BA85577FQ28079013-92A8FC91-6EEF-41E0-8126-708A5725FA9AQ28245467-5715783F-DD16-4624-A8DF-03037658433BQ28535227-2D44D634-8C28-44F6-81FC-EE738EA7EF45Q28539449-E1EB849C-224C-4A46-AC3B-9C265EFC789AQ28972291-7B3CCA94-6B26-4313-8612-9A89ABC31C10Q29614537-A6409D53-C1A4-4429-ACB0-A62F6A5653B5Q29617680-D28285E1-8B69-4153-B5F6-2F5E70F09617Q33389519-9A661BB3-FD93-418E-ACED-8AC0C4C5D321Q33391770-717FE134-9E43-4004-9F59-7643CD60358DQ33392046-DEB90880-7BB7-4F30-BD96-771C469303E6Q33393174-77410E5B-0CBD-4C83-A123-B58925361D36Q33395853-34ECB7B1-DA46-467B-A59E-34EEFAF15764Q33403848-4664AA37-2D2D-41D4-ABB0-3E5586A6100BQ33406542-2834839C-19AC-497C-B5F5-3087D0A469D4Q33407676-379794A5-581A-4990-8637-5B8F8FBF983BQ33409913-85183316-A0A3-4C42-BC2B-C4111DC543E5Q33413742-D5242777-5E24-48D5-B916-67497D5ADA6EQ33434465-52CBDE50-7783-47B1-9F19-3E0355EBA682Q33500786-A0204457-606F-45B2-92C4-80CA9666AB7DQ33633424-BA1B13E4-A306-4096-8F38-74F0C75772D4Q33648995-E516135E-7889-41DA-A454-207892A8F98AQ33655366-0C1C1477-7CAD-499B-B66A-9143FEF676F8Q33718025-EC8060F9-F053-401B-812C-FD2F49906FF9Q33726477-E5B31889-F545-476E-BBF0-C5610A38A23FQ33728605-FA993C62-06AA-4DB9-A66F-B5AC0756F12BQ33739313-97CF4E36-CC59-4B59-B25B-03B25F19F7F4Q33772197-2A42272F-E8A5-477A-BD00-B2FCDD6727BBQ33794403-9668B90D-745A-45DD-AE5E-1273A1A157AAQ33803564-FEDD7F82-025D-4F10-8724-ADFB61E34BE1Q33866151-3E5CAF9A-4D47-4B30-861A-EB8A1DCF009F
P2860
Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Phase II study of sunitinib ma ...... an anthracycline and a taxane.
@en
Phase II study of sunitinib ma ...... an anthracycline and a taxane.
@nl
type
label
Phase II study of sunitinib ma ...... an anthracycline and a taxane.
@en
Phase II study of sunitinib ma ...... an anthracycline and a taxane.
@nl
prefLabel
Phase II study of sunitinib ma ...... an anthracycline and a taxane.
@en
Phase II study of sunitinib ma ...... an anthracycline and a taxane.
@nl
P2093
P356
P1476
Phase II study of sunitinib ma ...... an anthracycline and a taxane.
@en
P2093
Anthony D Elias
Bonne J Adams
Carlo L Bello
Charles M Baum
Harold J Burstein
Hope S Rugo
Kathy D Miller
Mary Lehman
Melody A Cobleigh
Peter D Eisenberg
P304
P356
10.1200/JCO.2007.14.5375
P407
P577
2008-03-17T00:00:00Z